A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : RAF / rapidly accelerated fibrosarcoma

[Related PubMed/MEDLINE]
Total Number of Papers: 46
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   RAF  (>> Co-occurring Abbreviation)
Long Form:   rapidly accelerated fibrosarcoma
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 A serine-rich effector from the stripe rust pathogen targets a Raf-like kinase to suppress host immunity. Pst
2022 ALDH6A1 weakens the progression of colon cancer via modulating the RAS/RAF/MEK/ERK pathway in cancer cell lines. ALDH6A1, CC, COAD, ERK, MEK, MMP, oe, qRT-PCR, RAS, si-ALDH6A1
2022 Colon Cancer Pharmacogenetics: A Narrative Review. 5-FU, CapeOX, DPDY, FOLFOX, MTHFR, RAS, TSYM
2022 Development of a potent small-molecule degrader against oncogenic BRAFV600E protein that evades paradoxical MAPK activation. BRAF, PROTACs, UPS
2022 Effect of propiconazole on neutrophil extracellular traps formation: Assessing the role of autophagy. ERK, NETs, PCZ, PI3K, SD
2022 KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors. MAPK, RAS
2022 lncRNA MIR4435-2HG Accelerates the Development of Bladder Cancer through Enhancing IQGAP3 and CDCA5 Expression. BCa, CCK-8, CDCA5, EdU, ERK, IQGAP3, lncRNAs, MEK, miR-2467-3p, MIR4435-2HG, RAS, RIP
2022 RAF22, ABI1 and OST1 form a dynamic interactive network that optimizes plant growth and responses to drought stress in Arabidopsis. ABA, ABI1, OST1
2022 Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma. BRAF, cTCC, PDGFR-beta, VEGFR
10  2021 A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker. ERK, MEK, NSCLC
11  2021 Genetic Basis and Therapies for Vascular Anomalies. A/VEGFR, HGF, RAS, VEGF
12  2021 LY294002 and sorafenib as inhibitors of intracellular survival pathways in the elimination of human glioma cells by programmed cell death. PI3K
13  2021 PF-3845, a Fatty Acid Amide Hydrolase Inhibitor, Directly Suppresses Osteoclastogenesis through ERK and NF-kappaB Pathways In Vitro and Alveolar Bone Loss In Vivo. ERK, FAAH, MEK, NF-kappaB, NFATc1, RANKL
14  2021 The long noncoding RNA MEG3 regulates Ras-MAPK pathway through RASA1 in trophoblast and is associated with unexplained recurrent spontaneous abortion. CCK-8, ChIP, ERK, EZH2, GSE, MEG3, MEK, RASA1, RIP, URSA
15  2020 Novel Imidazo[2,1-b]oxazole Derivatives Inhibit Epithelial Cell Transformation and Triple Negative Breast Cancer Tumorigenesis. TNBC
16  2019 A new regulatory mechanism for Raf kinase activation, retinoic acid-bound Crabp1. ATRA, CRABP1, HSQC, RBD
17  2019 Activation of extracellular signal-regulated kinase is associated with hepatocellular carcinoma with aggressive phenotypes. ERK, HCC, HGF, MEK, RAS
18  2019 Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods. GST
19  2019 In-cell single-molecule FRET measurements reveal three conformational state changes in RAF protein. ALEX, smFRET, WT
20  2019 miR-574-3p inhibits proliferation and invasion in esophageal cancer by targeting FAM3C and MAPK1. ERK, FAM3C, MAPK1, MEK, miR-574-3p, PI3K
21  2019 Mitogen-Activated Protein Kinase (MAPK): New Insights in Breast Cancer. ERK, MAPK, MEK, RAS
22  2019 Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies. BRAF, MAPK, RAI, RAI-R, RAS, RTK, SLC5A5
23  2019 Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells. Bax, ERK, ICAM-1, JAK1, MEK, MMP-9, RAS, RT-qPCR, SDC1, STAT3
24  2019 The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases. AMPK, ERK, MEK, mTOR, PI3K, RAS
25  2018 BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers. MAPK/ERK
26  2018 Chemoproteomic Discovery of a Ritanserin-Targeted Kinase Network Mediating Apoptotic Cell Death of Lung Tumor Cells. NSCLC, SCLC
27  2018 High expression level of MMP9 is associated with poor prognosis in patients with clear cell renal carcinoma. ccRCC, ERK1, ETS1, GEO, IHC, MAPK, MEK2, MMP-9
28  2018 Human Epidermal Growth Factor Receptor-2 Promotes Invasion and Metastasis in Gastric Cancer by Activating Mitogen-activated Protein Kinase Signaling. ERK, GC, HER2, JNK, MAPK
29  2018 Lymphocyte-Specific Protein-1 Controls Sorafenib Sensitivity and Hepatocellular Proliferation through Extracellular Signal-Regulated Kinase1/2 Activation. ERK, HCC, LSP1, LSP1KO, LSP1TG
30  2018 New tools for evaluating protein tyrosine sulfation: tyrosylprotein sulfotransferases (TPSTs) are novel targets for RAF protein kinase inhibitors. TPSTs
31  2018 Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents. MAPK
32  2018 Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner. ERK, MAPKs, NK, TKIs
33  2018 Structural snapshots of RAF kinase interactions. MAPK, RAS
34  2017 A systematic review of targeted agents for non-small cell lung cancer. AKT, ALK, EGFR, EML4-ALK, MET, mTOR, NSCLC, RAS, ROS1, TA
35  2017 Attenuated phenotype of Costello syndrome and early death in a patient with an HRAS mutation (c.179G>T; p.Gly60Val) affecting signalling dynamics. CS
36  2017 Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. ERK, HCC, MEK, RAS
37  2016 Extracellular matrix stiffness causes systematic variations in proliferation and chemosensitivity in myeloid leukemias. ---
38  2015 Cytosolic phospholipase A2alpha regulates G1 progression through modulating FOXO1 activity. cPLA2alpha, FOXO1, PGE2
39  2015 Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma. CAFs, NRG1
40  2015 Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site. RALGDS, RBDs
41  2015 Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. RAS
42  2015 The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor Paradox. ---
43  2015 The discovery and development of sorafenib for the treatment of thyroid cancer. DTCs, RAI, RTKs
44  2014 Dimerization-induced allostery in protein kinase regulation. EGFR, RNase L
45  2013 CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo. RAS
46  2012 Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib. cAMP, ERK, p-ERK, PC2, PKA, RAS, WT